Class 4 Medicines Defect Information: Tramadol Hydrochloride 50mg capsules (Strandhaven Ltd t/a Somex Pharma Ltd) Updated

Update 07/12/2023:

The update includes corrections to the batch numbers detailed in the notification which were incorrectly provided by the MAH at the time of issue (highlighted in red in the table below).

Class 4 Medicines Defect Information: Tramadol Hydrochloride 50mg capsules (Strandhaven Ltd t/a Somex Pharma Ltd)

Drug alert number: EL(23)A/41

Date issued: 06 December 2023

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Tramadol Hydrochloride 50mg capsules (Somex Pharma Ltd)

Company name: Strandhaven Ltd t/a Somex Pharma

Product name: Tramadol Hydrochloride 50mg Capsules, Hard, PL 15764/0138


Batch Number Expiry Date Pack Size First Distributed
SMI2201 Mar-24 100 27/10/2022
SMI2202 Apr-24 100 27/10/2022
SMI2203 Apr-24 100 27/10/2022
SMI2204 Apr-24 100 27/10/2022
SMI2205 Sep-25 100 08/02/2023
SMI2206 Sep-25 100 01/02/2023
SMI2207 Sep-25 100 01/02/2023
SMI2208 Nov-25 100 03/04/2023
SMI2209 Nov-25 100 03/04/2023
SMI2210 Nov-25 100 13/04/2023
SMI2211 Nov-25 100 13/04/2023
SMI2212 Nov-25 100 15/04/2023
SMI2301 Dec-25 100 15/04/2023
SMI2302 Dec-25 100 15/04/2023
SMI2303 Dec-25 100 03/04/2023
SMI2304 Dec-25 100 03/04/2023
SMI2305 Dec-25 100 03/04/2023
SMI2306 Jan-26 100 13/06/2023
SMI2307 Jan-26 100 13/06/2023
SMI2308 Jan-26 100 13/06/2023
SMI2309 Jan-26 100 13/06/2023
SMI2310 Jan-26 100 13/06/2023
SMI2311 Jan-26 100 13/06/2023
SMI2312 Feb-26 100 15/06/2023
SMI2313 Feb-26 100 15/06/2023
SMI2314 Feb-26 100 15/06/2023
SMI2315 Feb-26 100 15/06/2023
SMI2316 Feb-26 100 15/06/2023
SMI2317 Feb-26 100 15/06/2023
SMI2318 Feb-26 100 15/06/2023
SMI2319 Feb-26 100 15/06/2023
SMH2301 Dec-25 30 15/04/2023
SMH2303 Feb-26 30 15/06/2023

Active Pharmaceutical Ingredient: Tramadol Hydrochloride

Brief description of the problem

Strandhaven Limited t/a Somex Pharma has informed the MHRA regarding an error with the Patient Information Leaflets (PILs) that have been packed in the listed batches of Tramadol Hydrochloride 50mg Capsules, Hard. The PIL does not include the most up to date safety information for drug interaction of antidepressants with Tramadol, sleep-related breathing disorders, adrenal insufficiency, hiccups, and serotonin syndrome, and the need to seek medical advice if they occur. The information missing from the PILs is included below:

2. What you need to know before you take Tramadol

Warnings and precautions

  • If you suffer from depression and you are taking antidepressants as some of them may interact with tramadol

Tramadol can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep-related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor.

There is a small risk that you may experience a so-called serotonin syndrome that can occur after having taken tramadol in combination with certain antidepressants or tramadol alone. Seek medical advice immediately if you have any of the symptoms related to this serious syndrome (see section 4 ‘Possible side effects’).

Taking this medicine regularly, particularly for a long time, can lead to addiction. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.

Talk to your doctor or pharmacist or nurse if you experience any of the following symptoms while taking Tramadol:

  • Extreme fatigue, lack of appetite, severe abdominal pain, nausea, vomiting or low blood pressure. This may indicate that you have adrenal insufficiency (low cortisol levels).

If you have these symptoms, contact your doctor, who will decide if you need to take hormone supplement.

4. Possible side effects

Not known: frequency cannot be estimated from the available data

  • hiccups
  • Serotonin syndrome, that can manifest as mental status changes (e.g. agitation, hallucinations, coma), and other effects, such as fever, increase in heart rate, unstable blood pressure, involuntary twitching, muscular rigidity, lack of coordination and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea) (see section 2 ‘What you need to know before you take ’).
  • dependence and addiction (see section “How do I know if I am addicted?”).

Advice for healthcare professionals

There is no risk to product quality because of this issue, therefore the affected batches are not being recalled. Healthcare professionals are advised to exercise caution when dispensing the products and where possible, provide an updated PIL. The updated PIL is available electronically and can be downloaded from the Somex Pharma Website. If it is not possible to provide an updated PIL, please advise patients of the missing information, discuss if this medicine is still suitable for them, and the need to seek medical advice if these signs or symptoms occur.

Strandhaven Limited t/a Somex Pharma has confirmed that all future batches will contain the correct PIL. Upon request, Strandhaven Limited t/a Somex Pharma will post hard copies of the updated PIL to wholesalers and pharmacies so that any remaining stock in the dispensary can be supplemented with the correct PIL information (see contact details below).

View full alert here.

Advice for patients

No action is needed from patients. This issue is about missing information in the Patient information leaflets (PILs) in specific batches of Tramadol Hydrochloride 50mg film-coated tablets indicated for moderate to severe pain (pain reliever). The medication itself is not affected.

These products will have been prescribed and dispensed by qualified healthcare professional(s) responsible for your care. If you have concerns about a medicine you may be using, please contact your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Further Information

For more information, medical information queries, contact:, tel: 020 8590 9399, choose option 3 or 4.

For stock control queries, contact:, tel: 020 8590 9399, choose option 2.

Support the call for more funding by recording information about the informal advice you provide to patients over just one day.

Click Here